News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Data Published in Journal of Neuroimmunology Suggest Anti-Inflammatory Role for Lead VBL Therapeutics Compound in CNS Inflammatory Diseases


9/14/2010 9:35:23 AM

TEL AVIV, Israel--(BUSINESS WIRE)--VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the publication of preclinical data in the Journal of Neuroimmunology finding that its lead development candidate VB-201 significantly delayed the onset and severity of experimental autoimmune encephalomyelitis (EAE) in mice, the commonly used Multiple sclerosis (MS). These data further elucidate VB-201’s mechanism of action and, for the first time, suggest an anti-inflammatory role of VB-201 in central nervous system (CNS) diseases including MS. The article appears in the September 14, 2010 issue of the journal.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES